Latest Resistin Stories
An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.
The chance discovery of a genetic mutation that makes mice enormously fat but protects them from diabetes has given researchers at Boston University School of Medicine, USA, new insights into the cellular mechanisms that link obesity to Type 2 diabetes.
Chronic inflammation within fat tissue is now recognized as a contributor to the many negative consequences that come with obesity -- from diabetes to cardiovascular disease, according to Yuichi Oike of Kumamoto University in Japan. Researchers hope a new discovery will point to a targeted therapy designed to limit the impact of the obesity epidemic.
An exploration of the molecular links between insulin resistance and inflammation may have revealed a novel target for diabetes treatment, say scientists at the John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh of UPMC.
Obesity very often leads to insulin resistance, and now researchers reporting in the July 8 issue of Cell Metabolism, a Cell Press publication, have uncovered another factor behind that ill consequence.
A new biomarker may help identify people at greatest risk for heart failure.
Hollis-Eden Pharmaceuticals, a development-stage pharmaceutical company, has reported additional positive interim data from its on-going Phase I/II clinical trial with its investigational oral drug candidate Triolex in obese insulin resistant subjects.
The systemic inflammation associated with obesity has been ruled out as a link to asthma, New Zealand researchers said. "We were disappointed not to find a 'smoking gun' that would explain the common association between obesity and asthma," lead researcher Dr. D.
By Kanaka-Gantenbein, Christina Margeli, Alexandra; Pervanidou, Panagiota; Sakka, Sophia; Mastorakos, George; Chrousos, George P; Papassotiriou, Ioannis BACKGROUND: Although there is much evidence regarding the physiologic and pathogenic roles of the newly described adipokines retinol-binding protein 4 (RBP4) and lipocalin-2 as potential promoters of insulin resistance in obese adults, relatively little information exists regarding their roles in obese children.
A study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) has shown that a protein found in fat cells is a newly discovered cause of insulin resistance, establishing a previously unidentified molecular link between obesity and type 2 diabetes and offering a potential new target for the development of drugs to treat diabetes. The findings appear in the July 21, 2005, issue of the journal Nature.